Beximco inks manufacture & supply deal to target US
Beximco Pharmaceuticals has inked a manufacturing, supply and development deal with Adamis Pharmaceuticals to introduce generics to the US.
Bangladesh-based Beximco and Adamis plan to launch four drugs, targeting allergies and asthma in the US over the next three years. Furthermore, there are plans to co-develop certain drugs, some of which Beximco already produces for the European market.
"This is another achievement for the company and highlights our significant generic drug capabilities as we move closer towards becoming a global generic drug player, particularly in the US and Europe”, said Nazmul Hassan, managing director of Beximco Pharma.
